- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.01. | FDA adds warning to RSV shots from GSK, Pfizer | ||
| 08.01. | Kidney disease drugmaker Maze Therapeutics files for IPO | ||
| 08.01. | Tenvie raises $200M for brain drug R&D; Sana spikes on single patient's results | ||
| 08.01. | Galapagos, after setbacks, will split in two and revamp Gilead deal | ||
| 07.01. | Vertex, startup Orna to partner on gene editing research | ||
| 07.01. | Metsera reveals data supporting long-acting obesity shot | ||
| 07.01. | J&J says cancer drug combination showed survival benefit over Tagrisso | ||
| 07.01. | ALS drugs from Denali, Calico come up short, marking more failures for Healey trial | ||
| 06.01. | Orbis raises $93M to turn popular biologics into pills | ||
| 06.01. | 5 FDA decisions to watch in the first quarter of 2025 | ||
| 06.01. | Navigating future biopharma catalysts: What to expect at the 2025 J.P. Morgan Healthcare Conference | ||
| 06.01. | An evolution in leadership and vision for this pharma company | ||
| 02.01. | Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals | ||
| 02.01. | Neumora plummets on depression drug data | ||
| 02.01. | FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024 | ||
| 02.01. | 10 clinical trials to watch in the first half of 2025 | ||
| 20.12.24 | Ionis gets a milestone approval; Another top FDA official to step down | ||
| 20.12.24 | Novo's next-gen obesity drug misses expectations in closely watched trial | ||
| 19.12.24 | Roche sticks with Parkinson's drug despite second study failure | ||
| 19.12.24 | A venture firm breathes new life into an old NGM drug | ||
| 19.12.24 | Regeneron says study data support big bet on new blood thinners | ||
| 19.12.24 | Vertex 'ends the year in pain' as latest non-opioid drug data disappoint | ||
| 19.12.24 | Novartis shutters MorphoSys sites, lays off staff | ||
| 19.12.24 | Zepbound, Mounjaro shortages are resolved, FDA confirms | ||
| 19.12.24 | Ottimo raises $140M to compete in chase for new type of cancer drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
